MG Unit Trust

0.430

0.000

Volume:- -

Turnover:- -

Market Cap:93.27M

PE:- -

High:0.430

Open:0.430

Low:0.430

Close:0.430

52wk High:0.430

52wk Low:0.430

Shares:216.91M

Float Shares:114.90M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:27.78%

PB:0.98

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America

prnewswire

·

Nov 26, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MGC.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MGC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MGC.AU\",,,,,undefined,":{"symbol":"MGC.AU","market":"AU","secType":"STK","nameCN":"MG Unit Trust","latestPrice":0.43,"timestamp":1770699600000,"preClose":0.43,"halted":3,"volume":0,"delay":0,"changeRate":0,"nameEN":"MG Unit Trust","floatShares":114897018,"shares":216907272,"eps":0,"marketStatus":"Halted","change":0,"latestTime":"02-10 16:00:00 AEDT","open":0.43,"high":0.43,"low":0.43,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.43,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MGC.AU\",,,,,undefined,":{"symbol":"MGC.AU","floatShares":114897018,"roa":"27.78%","roe":"--","lyrEps":0,"shares":216907272,"dividePrice":0,"high":0.43,"amplitude":0,"preClose":0.43,"low":0.43,"week52Low":0.43,"pbRate":"0.98","week52High":0.43,"institutionHeld":0,"latestPrice":0.43,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0.43,"prevYearClose":0.43,"prevWeekClose":0.43,"prevMonthClose":0.43,"prevQuarterClose":0.43,"fiveDayClose":0.43,"twentyDayClose":0.43,"sixtyDayClose":0.43},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MGC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MGC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MGC.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586628532","title":"Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=2586628532","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586628532?lang=en_us&edition=fundamental","pubTime":"2025-11-26 09:06","pubTimestamp":1764119160,"startTime":"0","endTime":"0","summary":"SINGAPORE, Nov. 26, 2025 /PRNewswire/ --Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered in Buenos Aires, Argentina, with decades of experience in biosimilar development and commercialization, for the commercialization of Tuznue  across Latin American markets, including Argentina, Mexico, Bolivia, and Paraguay.Tuznue is a biosimilar to Herceptin , approved for the treatment of breast cancer and metastatic gastric cancer. Prestige Biopharma received European Commission  marketing authorization for Tuznue in September 2024. This approval marks a major milestone for the company's biosimilar portfolio, signaling progress in expanding access to cost-effective treatments across key global markets.Under the agreement, Biosidus secures exclusive rights to market and distribute Tuznue in Argentina, Mexico, Bolivia, and Paraguay, leveraging its exte","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prestige-biopharma-and-biosidus-enter-exclusive-license-agreement-for-tuznue-commercialization-in-latin-america-302626222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBC","MGC","EBC","BK4211","MGC.AU","PBH","BK4201","EC","BK4086"],"gpt_icon":1}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MGC.AU\",params:#limit:6,delay:true,,,undefined,":[]}}